This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by FIS.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News for CYAD
Celyad SA (CYAD) Upgraded to Buy: Here's What You Should Know
Is CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?
CYAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Beaten-Down Biotech Bets to Bounce Back in 2022
Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer
Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate
Other News for CYAD
Celyad Oncology announces the termination of its American Depository Receipt program
Celyad Oncology Announces the Termination of Its American Depository Receipt Program
Publication of a rectified transparency notification received from Fortress Investment Group LLC (Article 14 ยง1 of the Law of 2 May 2007)
Celyad Oncology SA: Publication of a Rectified Transparency Notification Received From Fortress Investment Group LLC
Celyad Oncology SA: Publication of a Transparency Notification Received from Tolefi SA